Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

Chiasson, Jean-Louis, Josse, Robert G, Gomis, Ramon, Hanefeld, Markolf, Karasik, Avraham, Laakso, Markku · 2002 · The Lancet

Abstract

Background The worldwide increase in type 2 diabetes mellitus is becoming a major health concern. We aimed to assess the effect of acarbose in preventing or delaying conversion of impaired glucose tolerance to type 2 diabetes. Methods In a multicentre, placebo-controlled randomised trial, we randomly allocated patients with impaired glucose tolerance to 100 mg acarbose or placebo three times daily. The primary endpoint was development of diabetes on the basis of a yearly oral glucose tolerance test (OGTT). Analyses were by intention to treat. Findings We randomly allocated 714 patients with impaired glucose tolerance to acarbose and 715 to placebo. We excluded 61 (4%) patients because they did not have impaired glucose tolerance or had no postrandomisation data. 211 (31%) of 682 patients in the acarbose group and 130 (19%) of 686 on placebo discontinued treatment early. 221 (32%) patients randomised to acarbose and 285 (42%) randomised to placebo developed diabetes (relative hazard 0.75 [95% CI 0.63-0.90]; p=0.0015). Furthermore, acarbose significantly increased reversion of impaired glucose tolerance to normal glucose tolerance (p Interpretation Acarbose could be used, either as an alternative or in addition to changes in lifestyle, to delay development of type 2 diabetes in patients with impaired glucose tolerance.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(02)08905-5

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

13 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 26 references

Research works printed but not linked: 1

  1. 1985, Diabetes mellitus, WHO Tech Rep Ser, 727, 7

Cited by

See all 2,543

Metadata

Authors
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M.
Affiliations
  • Centre Hospitalier de l’Université de Montréal (CA)
  • St. Michael's Hospital (CA)
  • Sheba Medical Center (IL)
  • University of Eastern Finland (FI)
Corresponding author
Chiasson, Jean-Louis
Venue
The Lancet
Publisher
Elsevier BV
Published
2002-06
Volume
359
Issue
9323
Pages
2072-2077
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2123744385
Cited by
2,543
References
26
Citations by year
2026: 30 · 2025: 48 · 2024: 75 · 2023: 69 · 2022: 78 · 2021: 85 · 2020: 90 · 2019: 81 · 2018: 96 · 2017: 84 · 2016: 110 · 2015: 108 · 2014: 116 · 2013: 105 · 2012: 124
FWCI
82.32
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Natural Antidiabetic Agents Studies
Keywords
acarbose, type 2 diabetes prevention, impaired glucose tolerance, alpha-glucosidase inhibitors, diabetes prevention, oral glucose tolerance test, flatulence, diarrhea, lifestyle intervention
MeSH terms
Blood Glucose, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Glucose Intolerance, Acarbose

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. https://app.cochat.ai/papers/10.1016/s0140-6736(02)08905-5
The paper
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., & Laakso, M. (2002). Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. The Lancet. https://doi.org/10.1016/s0140-6736(02)08905-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.